Results 191 to 200 of about 3,137,400 (295)

Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure-activity relationships, and ADMET liabilities. [PDF]

Med Chem Res
Zhao W, Bie B, Wang J, Liu X, Fang H, Niu R.   +5 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. [PDF]

Pharmaceuticals (Basel)
Bisi N, Hamze A.
europepmc   +1 more source

The Brazilian medicinal chemistry from 1998 to 2008 in the Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Bioorganic and Medicinal Chemistry Letters and European Journal of Medicinal Chemistry

Revista Virtual de Química, 2009
Renato S. Bastos, Bárbara V. Silva, Angelo C. Pinto   +2 more
openaire   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands. [PDF]

J Med Chem
Paradiso E, Jakopin Ž.
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents. [PDF]

Int J Mol Sci
Panda SS, Bekheit MS, Aboshouk DR, Sivakumar S, Morsy MA, Abdur-Rahman M, Fahmi A, Girgis AS.   +7 more
europepmc   +1 more source

Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling

Molecular Oncology, EarlyView.
This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan, Beatriz Martín‐Gracia, Eva Bassols‐Citores, Krizia Sagini, Maria K. Andersen, Tuula A. Nyman, May‐Britt Tessem, Morten B. Rye, Alicia Llorente   +8 more
wiley   +1 more source